Stopping semaglutide or tirzepatide treatments for type 2 diabetes and obesity can reverse their cardiovascular benefits within months, according to a study published in BMJ Medicine. Researchers at Washington University School of Medicine in St. Louis found that interrupting GLP-1 drug therapy for as little as six months was associated with a meaningful increase in the risk of heart attack, stroke, and death compared to continuous use.
Cardiovascular Risks Rise After Stopping Semaglutide and Tirzepatide
Approximately one in eight U.S. adults now uses GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound. While these drugs help manage blood sugar and drive weight loss, new data shows their heart protection depends on uninterrupted adherence. According to senior study author Dr. Ziyad Al-Aly, chief of the Research and Development Service at the VA Saint Louis Health Care System and clinical epidemiologist at WashU Medicine, drug shortages, side effects, or cost often lead patients to stop these medications.
Pro Tip: Healthcare providers emphasize that managing side effects proactively can prevent premature treatment discontinuation and protect long-term heart health.
The research team tracked more than 333,000 U.S. veterans with type 2 diabetes over three years. They compared 132,551 patients prescribed GLP-1 medications against 201,136 patients taking sulfonylureas, such as glipizide, glimepiride, and glyburide. The data revealed that 26% of GLP-1 users stopped the medication entirely, while 23% experienced a treatment gap of at least six months before restarting.
Continuous Treatment Versus Treatment Gaps
Patients who remained on GLP-1 drugs continuously for the full three-year study period experienced an 18% lower risk of major adverse cardiovascular events compared to the sulfonylurea group, translating to roughly four fewer events per 100 people. This continuous use builds protection over time.
However, pausing the medication quickly erodes those gains. A treatment gap of just six months before resuming therapy led to a 4% to 8% increase in cardiovascular risk compared to continuous use. Patients who stopped therapy for one year faced a 14% higher risk, and those who remained off the drugs for two years saw their risk increase by up to 22%.
The Metabolic Reversal Mechanism Behind the Risk
According to Dr. Robert Glatter, assistant professor of Emergency Medicine at Zucker School of Medicine at Hofstra/Northwell and an attending physician in the Department of Emergency Medicine at Lenox Hill Hospital, who was not involved in the study, GLP-1 drugs slow atherosclerotic plaque growth, reduce inflammation, lower blood pressure, and improve blood sugar control. When patients stop taking them, the body undergoes what researchers call a metabolic reversal.
Did You Know? Weight regain is visible after stopping GLP-1 therapy, but the underlying metabolic reversal—including rising blood pressure, worsening cholesterol, and surging inflammation—happens inside the cardiovascular system.
Dr. Al-Aly noted that restarting the medication helps restore some protection, but only partially, indicating that discontinuation leaves a lasting physiological scar. Because cardiovascular benefits accumulate gradually but disappear much more quickly, researchers urge health systems to treat medication adherence as a primary clinical outcome rather than an afterthought.
Frequently Asked Questions
What are the primary reasons patients stop taking GLP-1 drugs?
According to Washington University School of Medicine researchers, many patients discontinue semaglutide or tirzepatide treatments due to medication costs, persistent side effects, or drug shortages.
Does restarting Ozempic or Wegovy restore lost heart benefits?
Research published in BMJ Medicine shows that restarting GLP-1 therapy restores some cardiovascular protection, but it only partially reverses the increased heart attack and stroke risk accrued during treatment gaps.
How long can you stop taking GLP-1 medications before heart benefits fade?
Data from the Washington University study indicates that cardiovascular benefits begin to weaken after a treatment gap of just six months, with risks escalating the longer a patient stays off the medication.
What are your thoughts on maintaining long-term GLP-1 adherence? Share your experiences or questions in the comments below, and subscribe to our newsletter for the latest updates on medical research and cardiovascular health.
Related reading